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Abstract: 42 
 43 
Lycopene is the red pigment in tomatoes and tomato products and is an 44 
important dietary carotenoid found in the human organism. Lycopene-45 
isomers, oxidative lycopene metabolites and apo-lycopenoids are found in 46 
the food matrix. Lycopene intake derived from tomato consumption is 47 
associated with alteration of lipid metabolism and a lower incidence of 48 
cardiovascular diseases (CVD). Lycopene is mainly described as a potent 49 
antioxidant but novel studies are shifting towards its metabolites and their 50 
capacity to mediate nuclear receptor signalling. Di-/tetra-hydro-derivatives of 51 
apo-10´-lycopenoic acid and apo-15´-lycopenoic acids are potential novel 52 
endogenous mammalian lycopene metabolites which may act as ligands for 53 
nuclear hormone mediated activation and signalling. In this review, we 54 
postulate that complex lycopene metabolism results in various lycopene 55 
metabolites which have the ability to mediate transactivation of various 56 
nuclear hormone receptors like RARs, RXRs and PPARs. A new mechanistic 57 
explanation of how tomato consumption could positively modulate 58 
inflammation and lipid metabolism is discussed. 59 
 60 
 61 
 62 
 63 
64 
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1. Health beneficial effects of lycopene are linked to various nuclear hormone 65 
receptor signalling pathways 66 
 67 
High consumption of fruit and vegetables is associated with a lower risk of 68 
CVD (Leenders et al., 2013). Dietary carotenoids, in particular lycopene, are 69 
among the constituents in various fruits and vegetables and their dietary 70 
intake and serum levels are linked to these protective effects. Mechanistic 71 
explanations to lycopene effects are mainly focused on its well established 72 
antioxidant activity via inhibition and scavenging of reactive oxygen species 73 
(ROS) production. However, current research is exploring novel mechanisms 74 
such as modulation of inflammatory responses (Palozza et al., 2010) and 75 
activation of nuclear hormone receptors (Aydemir et al., 2012; Aydemir et al., 76 
2013; Ben-Dor et al., 2001; Eroglu and Harrison, 2013; Harrison et al., 2012; 77 
Lindshield et al., 2007; Stahl and Sies, 1996).  78 
 79 
Epidemiological studies suggest a negative association between low serum 80 
lycopene concentrations and high risk of coronary events and stroke (Karppi 81 
et al., 2012; Rissanen et al., 2001), although this has been refuted by others 82 
(Karppi et al., 2013; Sesso et al., 2005). In a cross-sectional study, biomarkers 83 
for the risk of coronary biomarkers (total cholesterol and total cholesterol:HDL 84 
ratio) were clinically improved in women consuming 24.3 mg of 85 
lycopene/day of tomato rich products compared to women consuming the 86 
lowest intake of 3.6 mg lycopene/day (Sesso et al., 2012). To further explain 87 
this, evidence from experimental studies suggests that lycopene may act 88 
through modulation of inflammation in atherosclerotic processes and obesity 89 
(Palozza et al., 2010).  90 
 91 
Key regulators of metabolic pathways linked to adipogenesis as well as to 92 
inflammation mechanisms in the cardiovascular system are the Peroxisome 93 
Proliferator Activated Receptors (PPARα, γ, δ/β)(Menendez-Gutierrez et al., 94 
2012). Synthetic ligands of PPAR’s have shown to exert beneficial effects 95 
identified by lower CVD risk markers (Millar, 2013). PPARα agonists are limiting 96 
 4 
postprandial lipoprotein responses and increase HDL-cholesterol via lowering 97 
of chylomicron production (Colin et al., 2012). PPARγ agonists down-regulate 98 
inflammation via immunomodulation of adipose tissue which results in 99 
improved insulin sensitivity (Cipolletta et al., 2012). PPARδ/β agonists inhibit 100 
macrophage foam cell formation leading to lower inflammatory responses 101 
induced by very low density lipoprotein (Bojic et al., 2012). PPAR’s also 102 
respond to diet-related ligands (reviewed in (Schupp and Lazar, 2010)) and 103 
can therefore modulate target gene expression. This regulation has the 104 
potential to modify lipid metabolism and inflammation pathways.  105 
 106 
Cell studies using human macrophages have already shown that lycopene is 107 
able to lower the formation of atherosclerotic plaques by lowering pro-108 
inflammatory responses via NF-kB activation and ROS production (Lorenz et 109 
al., 2012; Palozza et al., 2011b). Lycopene also attenuates foam cell formation 110 
during cholesterol homeostasis via prevention of PPARγ activation (Palozza et 111 
al., 2011a). These cell studies are further supported by evidence from animal 112 
models. Lycopene supplementation in atherosclerotic rabbits induced by 113 
high cholesterol diet showed a reduction in total and LDL cholesterol in serum 114 
but no modifications in aortic lesions (Lorenz et al., 2012). These results support 115 
further evidence from human intervention trials on endothelial function 116 
(Stangl et al., 2011).  117 
 118 
Lycopene activity may be related to PPAR-mediated signalling, thus we 119 
suggest that lycopene-metabolites could act as ligands of PPAR´s which can 120 
activate transcriptional signalling. Consequently, the activated PPAR forms 121 
together with an RXR are, in our case, the major active transcription factors in 122 
diet induced gene expression. Here we describe the current evidence on 123 
these novel mechanisms with the aim to propose an explanation focused on 124 
inflammation and lipid metabolism to evaluate how lycopene intake is 125 
related to beneficial health effects.  126 
 127 
2. Lycopene and lycopene-metabolites in the food matrix  128 
 5 
 129 
The main source of lycopene in Western diets is tomato (Solanum 130 
lycopersicum L.), the second most consumed vegetable in the world. In the 131 
USA, it has been estimated that 80% of lycopene is consumed through 132 
tomatoes and tomato products (Clinton, 1998). Lycopene content in tomato 133 
can vary depending on the variety of the fruit, its ripeness degree, but also on 134 
the environmental conditions (temperature, soil, etc.) (Dumas et al., 2003).  135 
 136 
In red tomatoes, lycopene is usually present in its most thermodynamic stable 137 
form, the (all-E)-form. Tomato and tomato based products also contain 138 
various geometric lycopene-isomers, hydroxy- / oxo- / epoxy-metabolites in 139 
addition to apo-lycopenoids (Figure 1), though in lower concentrations than 140 
(all-E)-lycopene.  (All-E)-lycopene can undergo isomerisation during 141 
processing and various lycopene isomers are detectable in processed 142 
tomato products (Chanforan et al., 2006). Lycopene 1,2-epoxide and 5,6-143 
epoxide have been found in fresh tomato (Ben-Aziz et al., 1973), whereas only 144 
lycopene 1,2-epoxide was found in tomato paste and juice (Khachik et al., 145 
1998). Another lycopene epoxide, namely the 2,6-cyclolycopene-1,5 epoxide 146 
has been found in its 2 diastereoisomeric forms in these tomato food products 147 
(Khachik et al., 1998). This molecule could be the precursor of 2,6-148 
cyclolycopene-1,5 diol, previously detected in tomato paste (Tonucci et al., 149 
1995). Other oxidative lycopene-metabolites containing alcohol groups 150 
(Yokota et al., 1997) were isolated in low quantity from tomato puree and 151 
identified as 1,5-di-hydroxy-iridanyl-lycopene and 2,6-cyclolycopene-1-152 
methoxy-5-ol and 1,16-di-dehydro-2,6-cyclolycopene-5-ol (Yokota et al., 153 
2003).  154 
 155 
Lycopene or oxidative lycopene-metabolites can further be converted to 156 
apo-lycopenoids via targeted enzymatic cleavage or via unspecific 157 
chemical cleavage of lycopene´s hydrocarbon structure. Long-chain apo-158 
lycopenoids, i.e. apo-6’-lycopenal and apo-8’-lycopenal have been found in 159 
extracts of tomato paste (Winterstein et al., 1960) with an estimated content 160 
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of 5 μg/g. Later, these were also found in lower levels in raw tomatoes, and in 161 
addition further three apo-lycopenals (apo-6‘-, apo-8‘-, apo-10‘-, apo-12‘- 162 
and apo-14‘-lycopenals) were partly identified and partly predicted to be 163 
present in tomato paste and in lower levels in raw tomatoes (Kopec et al., 164 
2010).  165 
 166 
 167 
3. Lycopene metabolism and molecular mechanisms of action 168 
 169 
Lycopene mechanism of action in biological systems has been thoroughly 170 
studied and mainly described as being related to its antioxidant activity 171 
(Erdman et al., 2009; Stahl and Sies, 1996). In addition, lycopene activity could 172 
be mediated through its known and still unknown metabolites (Aydemir et al., 173 
2012; Aydemir et al., 2013; Ben-Dor et al., 2001; Dela Sena et al., 2013; Eroglu 174 
and Harrison, 2013; Ferreira et al., 2003; Stahl et al., 2000). These unknown 175 
metabolites could be the relevant bioactive molecules because they are 176 
comparable to the structure of the retinoic acids which are the major 177 
biologically active metabolites of -carotene. The possibility that lycopene 178 
and/or its metabolites act as ligands to initiate nuclear hormone receptor 179 
mediated signalling has not been a major research focus but recent 180 
observations by us and others point towards this direction (Aydemir et al., 181 
2012; Aydemir et al., 2013; Gouranton et al., 2011). Using reporter animals for 182 
the retinoic acid reporter element (RARE), we found that lycopene can 183 
activate RARE-mediated signalling in various organs in a similar fashion to that 184 
of retinoic acids (Aydemir et al., 2012). Based on our own observations 185 
(Aydemir et al., 2013), we hypothesized that retinoid-like lycopene 186 
metabolites could act as bioactive molecules which can interact with 187 
RAR/RXR (Aydemir et al., 2013; Gouranton et al., 2011). Recently, we identified 188 
the endogenous RXR-ligand, 9-cis-13,14-dihydroretinoic acid which may also 189 
indirectly originate from tomatoes and tomato products (Rühl et al., 2015). 190 
RXR-ligands can also activate various heterodimers like RXR-LXR´s and RXR-191 
PPAR´s. These are involved in glucose and lipid homeostasis (Dawson and Xia, 192 
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2011; Perez et al., 2011; Shulman and Mangelsdorf, 2005; Shulman et al., 2004). 193 
Thus, RAR and RXR-ligands derived from tomato provide an alternative 194 
mechanistic explanation to the beneficial effects of lycopene intake on CVD 195 
prevention (Dawson and Xia, 2011; Liu et al., 2000; Miyazaki et al., 2010; Perez 196 
et al., 2011). We propose that based on lycopene-mediated RAR- and RXR-197 
pathways the key lycopene derived substances responsible for these RAR- 198 
and RXR-mediated effects are the apo-15´-carotenoid acids, in particular di-199 
/tetra-hydro-apo-15´-lycopenoic acids (figure 2). These are linear retinoic 200 
acid analogues comparable to β-carotene metabolites which are potent 201 
activators of several cell and receptor mediated mechanisms. 202 
 203 
Other lycopene derivatives such as apo-10´-lycopenoic acid (Aydemir et al., 204 
2013; Ford et al., 2010; Gouranton et al., 2011) and in particular di-/tetra-205 
hydro-apo-10´-lycopenoids can also act as ligands of nuclear hormone 206 
receptors. Relevant receptors to focus upon as a potential target for these 207 
ligands are the PPAR´s. PPAR´s bind a large variety of PUFAs and their 208 
metabolites (Forman et al., 1997; Forman et al., 1995; Kliewer et al., 1995; 209 
Shiraki et al., 2005). Many of these PUFAs and PUFA-metabolites are of longer 210 
chain length than the apo-15´-lycopenoids. PUFA-metabolite chain length is 211 
more in the range of apo-10´-lycopenoids or apo-12´-lycopenoids, which 212 
suggest that these structures are more likely potential ligands. Apo-10´-213 
carotenoids are described as BCO2-metabolites originating from excentric 214 
cleavage of carotenoids and lycopene seems to be a good substrate for this 215 
metabolic cleavage pathway (Hu et al., 2006; Lobo et al., 2012). Apo-10´-216 
lycopenoic acid may origin from dietary lycopene either as products of 217 
oxidation (via BCO2-cleavage) or isomerisation and oxidation (figure 2) 218 
(Amengual et al., 2013; Hu et al., 2006). To date, apo-10´-lycopenoic acid has 219 
not been identified to be present endogenously (Gouranton et al., 2011; Hu 220 
et al., 2006), but recently 7,8-di-hydro-apo-10´-lycopenoic acid has been 221 
proposed as a potential endogenous lycopene metabolite in mammals 222 
(Gouranton et al., 2011). In addition, apo-10’-lycopenal has been predicted 223 
to be present  together with other apo-lycopenals in human blood serum 224 
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after tomato juice consumption for 8 weeks (Kopec et al., 2010). Apo-10´-225 
lycopenal and apo-10´-lycopenoic acid have been synthesized (Reynaud et 226 
al., 2011) and further tested in various in vitro and in vivo models for nuclear 227 
receptor activation potential (Catalano et al., 2013; Gouranton et al., 2011; 228 
Reynaud et al., 2011). To support the potential role of these lycopene 229 
metabolites as PPAR ligands we present novel results of interaction studies of 230 
apo-10’-lycopenoic and apo-10’-lycopenal with RXR and PPAR’s in two 231 
different systems (Figure 3 and 4).  232 
 233 
 234 
4. Novel activities of lycopene metabolites and potential lycopene 235 
metabolites 236 
 237 
In this review, we show novel data originating from COS1-based reporter cell 238 
lines. We observed no RXR and PPARα, δ/β and γ activation potential for apo-239 
10’-lycopenal and apo-10’-lycopenoic acids, neither in a potential 240 
physiological or nutritional relevant range at lower nM concentrations (data 241 
not displayed, because treatments ranging from 10-9, 10-8, 10-7 and 10-6M 242 
were all comparable to control-treatments) nor at higher concentrations of 243 
10-5M (figure 3). This indicates no biological relevant direct interaction with 244 
nuclear receptors RXR and PPARα, δ/β, γ.  245 
 246 
However, when other indirect in vitro reporter techniques like target gene 247 
expression analysis in MM6 cells (figure 4) were used, we observed that one 248 
common PPAR-target gene, namely ADRP / PLIN2, was significantly induced 249 
by apo-10´-lycopenal or -lycopenoic acid at 10-5M (figure 4a) to an extent 250 
comparable to the PPARα synthetic ligand GW7647 used at relevant active 251 
concentrations of 10-6M (figure 4b). Contrary, the expression of other PPAR / 252 
RXR-target genes like the enzymes BCO1 (Boulanger et al., 2003) and BCO2 253 
(Gericke et al., 2013) were either non-affected or non-conclusively regulated 254 
by these metabolites, this was also confirmed in studies by our groups 255 
(Reynaud et al., 2011). This shows that PPAR-mediated signalling of apo-10´-256 
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lycopenoids needs further attention, in particular for apo-10´-lycopenal and 257 
apo-10´-lycopenoic acid metabolites. 258 
 259 
Apo-10’-lycopenoic acid has not been found yet as an endogenous 260 
metabolite in vivo and apo-10’-lycopenal has been predicted to be present 261 
in human plasma at a concentration of 0.28 ± 0.10 10-9M following a 262 
supplementation diet with tomato juice for 8 weeks (Kopec et al., 2010). The 263 
concentrations we used in MM6 cell model were higher than the nutritional 264 
relevant levels but comparable to concentrations used in the COS1-based 265 
reporter cell models. We hypothesize based on our results (Gouranton et al., 266 
2011) and based on results from other studies (Ip et al., 2013; Ip et al., 2015; 267 
Lian and Wang, 2008; Lian et al., 2007; Tan et al., 2014), that further metabolic 268 
activation may lead to novel biological active metabolites of apo-10´-269 
lycopenal, apo-10´-lycopenoic acid and/or lycopene. We additionally 270 
postulate that these novel metabolites can further directly interact and 271 
initiate PPARα, δ/β or γ-RXR mediated signalling in lower relevant endogenous 272 
or nutritional concentrations. These novel potential metabolites of apo-10’-273 
lycopenoids have not yet been identified, but we are in the process of further 274 
identification and investigation in regard to their physiological and nutritional 275 
relevance. 276 
 277 
In summary, the lycopene metabolite apo-10’-lycopenal and the potential 278 
lycopene-metabolite apo-10’-lycopenoic acid were not able to directly 279 
activate the nuclear hormone receptors RXR and PPARs in reporter cell lines. 280 
We speculate that further metabolites of apo-10’-lycopenal or apo-10’-281 
lycopenoic acid can interact with PPARs and RXR, as indicated by increased 282 
ADPR / PLIN2 (representing a PPAR-RXR target gene) expression in MM6-cell 283 
lines.  284 
 285 
 286 
5. Carotenoid metabolites as nuclear hormone receptor mediated signalling 287 
agonists: RXR / PPARα, δ/β, γ  288 
 10 
 289 
Based on simulation experiments using ligand-docking strategies, our groups 290 
are currently working to identify lycopene-metabolites which may have the 291 
potential to directly interact with nuclear hormone receptors. Using in silico 292 
docking studies, we suggest that di- or tetra-hydro-apo-10´-lycopenoic acids 293 
may be present endogenously or after nutritional interventions with tomato  294 
and its products (Gouranton et al., 2011). We propose that di- or tetra-hydro-295 
apo-10´-lycopenoic acids derivatives may also obtain PPAR-activating 296 
potential. Our hypothesis is based on the fact that these derivatives have 297 
similar shape and structure elements to those of PPAR-activators as shown in 298 
figure 5. Comparison of the docking poses (AutoDoc: (Morrison et al., 1999)) 299 
of the endogenous PPARγ-ligand 15-deoxy-d12,14-prostaglandin J2 (15-300 
deoxy-d12,14-PgJ2) and a potential lycopene-metabolite tetra-hydro-apo-301 
10´-lycopenoic acid after removal of the fibrate ligand (Nolte et al., 1998) 302 
shows similar organization in the PPARγ-binding pocket (figure 6). These 303 
observations let us postulate the potential of comparable shaped lycopene-304 
metabolites to be physiologically relevant for PPAR-mediated signalling. 305 
Several solutions for the docking of the more flexible lycopene metabolite 306 
were found. These multiple binding options are compatible with the large Y-307 
shaped ligand binding pocket of the PPAR subtypes (Markt et al., 2008). 308 
 309 
 310 
Conclusion  311 
 312 
We previously described the potential metabolite 7,8-di-hydro-apo-10´-313 
lycopenoic acid (Gouranton et al., 2011) originating from apo-10´-lycopenoic 314 
acid as a relevant lycopene metabolite derived from a food matrix and 315 
related to tomato / lycopene ingestion. PPAR-mediated systemic effects on 316 
lipid and glucose metabolism (in particular insulin sensitivity) are relevant to 317 
CVD risk factors. Based on our observations we postulate a connection 318 
between tomato intake, lycopene intake, lycopene metabolism and nuclear 319 
hormone receptor activation with a focus on the activation of RXR and 320 
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PPARα, δ/β, γ mediated pathways by lycopene metabolites. These novel 321 
potential lycopene metabolites are suggested to be di-/tetra-hydro-322 
derivatives of apo-15´-lycopenoic acid and apo-10´-lycopenoic acid. These 323 
metabolites may directly activate RXRs and PPARs in relevant endogenous or 324 
nutritional levels and may therefore alter gene expression which could result in 325 
physiological events related to inflammation processes, and/or lipid and 326 
glucose metabolism. These proposed interactions and pathways are a novel 327 
explanation for the protective health effects of lycopene and tomato, in 328 
particular those related to lipid metabolism, inflammation and insulin 329 
sensitivity. Our hypothesis guarantees to perform further targeted  330 
investigations to test and further elucidate these proposed mechanisms.   331 
 332 
Our groups will focus on the identification of various bioactive lycopene 333 
metabolites namely di-/tetra-hydro-derivatives of apo-15´-lycopenoic acid 334 
and apo-10´-lycopenoic acid using mainly HPLC-MS techniques. 335 
Unfortunately, the commonly used animal models, mice and rats, are not 336 
ideal models for carotenoid metabolism to be extrapolated to humans due to 337 
their different carotenoid nutri-kinetic. Nevertheless, gerbils can be an 338 
alternative because they are a model more suitable for comparisons with 339 
humans (Lee et al., 1999). When novel bioactive endogenous lycopene 340 
metabolites are identified, targeted organic synthesis can make them 341 
available in larger quantities for further biological testing in in vitro as well as in 342 
vivo models. We expect that via our planed experimental strategies soon we 343 
will find important new pathways to explain how tomatoes and tomato-344 
products can influence and prevent various chronic diseases relevant to 345 
humans. Targeted strategies based on identification of levels of these 346 
bioactive compounds derived from food intake can be used as disease 347 
biomarkers and will help to develop and plan better nutritional strategies for 348 
prevention of various chronic diseases based on altered lipid metabolism and 349 
inflammation. 350 
 351 
 352 
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Figure legends: 358 
 359 
Figure 1: Representative examples of lycopene-metabolites present in the 360 
human diet and organism: Lycopene isomers, oxidative lycopene metabolites 361 
and apo-lycopenoids. 362 
 363 
Figure 2: Lycopene metabolism and potential mediation of nuclear hormone 364 
receptor activation. Retinoic acid receptor (RAR), retinoid X receptor (RXR), 365 
Peroxisomal proliferator-activated receptor (PPAR). 366 
 367 
Figure 3: Relative induction of PPARa, PPARβ/δ, PPARγ and RXR activation in 368 
reporter cell lines by apo-10´-lycopenoic acid (apo10L-ac), apo-10´-369 
lycopenal (apo10L-ald) or PPAR-selective synthetic or endogenous activators 370 
of each specific receptor. WY14643 (PPARα), RSG (Rosiglitazone, PPARγ), 371 
GW0742 (PPARβ/δ) or 9CRA (RXR), each n=4..  372 
 373 
Used methodologies: COS1 cells were maintained in DMEM medium with 10% 374 
FBS, 5% L-glutamine, 1% penicillin streptomycin in 24-well plates and 375 
transfections were carried out in triplicates. Cells were transfected with equal 376 
amounts of relevant plasmids including Gal-RXR-LBD for RXR-reporter line or 377 
Gal-PPARδγ-LBD and Gal-RXR-LBD for PPAR-RXR reporter line, a reporter 378 
plasmid (luciferase MH100-TKLuc reporter construct with GAL-binding site 379 
(Nagy et al., 1999) and beta-galactosidase (for transfection efficiency 380 
calculation). The resulting normalized values are plotted as a bar graph ± the 381 
standard error. For details of transfection and measurements see (Rühl et al., 382 
2015).  383 
 384 
Figure 4: a) Fold induction of ADRP expression by apo-10´-lycopenoic acid 385 
(apo10L-ac), apo-10´-lycopenal (apo10L-ald), each n=3 or b) synthetic and 386 
selective activators of PPARα, β/δ and γ (WY14643 (PPARα), GW7845 (PPARγ), 387 
GW1516 (PPARβ/δ), each n=3.  388 
 389 
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Used methodologies; target gene analysis in Mono Mac 6 (MM6) cell in vitro: 390 
MM6 cells were maintained in RPMI-1640 medium containing 10% foetal 391 
bovine serum, 5% L-glutamine, supplemented with 0.1 % penicillin-392 
streptomycin and kept under controlled atmosphere at 37 °C and 5% CO2. 393 
Cells were subcultured every two days at a density of approximately 106 cells/ 394 
ml. Prior plating and counted by means of a Bürker chamber, centrifuged at 395 
1000 rpm with a Jouan C312 centrifuge and the obtained cell pellets were 396 
resuspended in RPMI-1640 medium containing 10% charcoal stripped serum, 397 
5% L-glutamine, supplemented with 0.1% penicillin-streptomycin. Cells were 398 
incubated for 6 hours and apo10L-ac, apo10L-ald and PPARα, δ/β, γ-selective 399 
synthetic agonists (at relevant active concentration of 10-6M) were added in 400 
an amount of 3 μl / well. Cells were incubated for 48 hours at 37 °C and 5 % 401 
CO2. Total RNA was isolated from cultured cells using Tri reagent solution 402 
according to the manufacturer´s instructions. Before real-time quantitative 403 
PCR (QRT-PCR), total RNA was reverse transcribed into cDNA using the Super 404 
Script II First-Standard Synthesis System (Invitrogen). QRT-PCR was carried out 405 
in triplicate using Taqman probes on an ABI Prism 7900. mRNA levels were 406 
normalized to the level of cyclophilin, which served as an internal control for 407 
the amount of RNA used in each reaction. The resulting normalized values are 408 
plotted as a bar graph ± the standard error. Sequence Detector software 409 
(version 2.1) was used for data analysis.  410 
 411 
Figure 5: PPAR activators: 15-deoxy-d12,14-PgJ2 (endogenous relevant PPARγ 412 
activator), Rosiglitazone (synthetic PPARγ activator) and 7,8,11,12-tetra-hydro-413 
apo-10´-lycopenoic acid (as a potential lycopene-derived PPAR activator). 414 
 415 
Figure 6: Docking poses of 15-deoxy-d12,14-PgJ2 (grey structure) and 416 
7,8,11,12-tetra-hydro-apo-10´-lycopenoic acid (yellow structure) bound to 417 
PPARγ (PDB code 2i4j). 7,8,11,12-tetra-hydro-apo-10´-lycopenoic acid binds in 418 
a similar way that others agonists of PPAR such as the fibrate derivative and 419 
the carboxylic acid have contact with Tyr473 and His 323 and His 449 and 420 
Ser289 (not shown for clarity).  421 
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DOCKING METHODS: The genetic algorithm (Morrison et al., 1999) 422 
implemented in AutoDock with the fibrate-bound PPARγ crystal structure 423 
((PDB code 2i4j) (Nolte et al., 1998) upon removal of the ligand was used to 424 
generate different PPARγ 15-deoxy-d12,14-PGJ2 and 7,8,11,12-tetra-hydro-425 
apo-10´-lycopenoic acid conformers by randomly changing torsion angles 426 
and the overall orientation of the molecules. A volume for exploration was 427 
defined in the shape of a three-dimensional cubic grid with a spacing of 0.3 Å 428 
that enclosed the residues that are known to make up the inhibitors binding 429 
pocket. At each grid point, the receptor's atomic affinity potentials for carbon 430 
and hydrogen atoms present in the studied ligands were pre-calculated for 431 
rapid intra- and intermolecular energy evaluation of the docking solutions for 432 
each inhibitor. To obtain additional validation of the proposed binding mode 433 
for the ligands, program GRID (http://www.moldiscovery.com) was also used 434 
to search for sites on the enzyme that could be complementary to the 435 
functional groups present in this inhibitor. The probes used were C3 (methyl 436 
CH3 group), COO- (aliphatic carboxylate). For the GRID calculations, a 18Å  437 
21Å  21Å lattice of points spaced at 0.5 Å was established at the binding site. 438 
The dielectric constants chosen were 4.0 for the macromolecule and 80.0 for 439 
the bulk water. Several solutions for the docking of the more flexible 7,8,11,12-440 
tetra-hydro-apo-10´-lycopenoic acid were found and are compatible with 441 
the large Y-shaped LBP of the PPAR subtypes (Markt et al., 2008).  442 
443 
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